Physician profile
Jonathan Sung
NPI 1477057859
$6,047.98
in general payments reported to CMS, 2019-2025
36 companies · $2,362 in 2025
The $2,362 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $491 · 2023: $867 · 2024: $2,328 · 2025: $2,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,503 · Education: $53.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,502.86 |
| Education | $53.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $813.90 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $643.08 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $494.62 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $444.86 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $374.40 | 2023-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $351.58 | 2023-2025 | |
| Amgen INC. | $332.70 | 2022-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $298.26 | 2023-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $261.79 | 2024-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $194.15 | 2023-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $181.56 | 2023-2025 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.21 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $164.20 | 2023-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $144.43 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $130.68 | 2024-2025 | Velphoro, Velphoro |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.